The Oncologist

From the Cover

• Regarding “Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies”
• Oncology Drug Approvals: Evaluating Endpoints and Evidence in an Era of Breakthrough Therapies
• A Case of Metastatic Atypical Neuroendocrine Tumor with ALK Translocation and Diffuse Brain Metastases
• Detection of an ALK Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNA
• Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
• Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer
• A Phase II Study of Everolimus Plus Oral Prednisone in Patients with Metastatic Renal Cell Cancer
• Targeting BRAF-Mutant Non-Small Cell Lung Cancer: From Molecular Profiling to Rationally Designed Therapy
• Clinical Variant Classification: A Comparison of Public Databases and a Commercial Testing Laboratory
• Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study
• Implementing a Fee-for-Service Cervical Cancer Screening and Treatment Program in Cameroon: Challenges and Opportunities
• p16, HPV, and Cetuximab: What Is the Evidence?
• ALK Fusion Detection in Circulating Free DNA: Finding an Important Needle in the Haystack
• Oncofertility: Fertile Ground for Conflict Between Patient Autonomy and Medical Values
• Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
• Comprehensive Genomic Profiling of Esthesioneuroblastoma Reveals Additional Treatment Options
• BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies
• FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
• National Policies Fostering Hospice Care Increased Hospice Utilization and Reduced the Invasiveness of End-of-Life Care for Cancer Patients
• Amani's Silence